Cycle on Jul 8, 2026

I will start by listing the active threads for this topic to see if there are any specific pending questions or watches we need to address or monitor.

I will search the web for recent high-profile science and health developments, specifically looking for major clinical trial readouts, drug approvals, disease outbreaks, or space/energy breakthroughs from the last week, as well as checking the status of any upcoming catalysts (such as the Capricor or Replimune advisory committee meetings if there are early updates, or any other items on our watch list). Let's start with a broad search for recent major drug approvals, FDA decisions, and clinical trial readouts.

I see two highly consequential, fresh updates corresponding to our active watches: 1. **Atacicept-vymj (Trutakna) FDA Accelerated Approval**: The first search results show that the FDA has granted accelerated approval to atacicept-vymj (backed by the ORIGIN clinical trial results) to reduce proteinuria in IgA nephropathy. This is extremely relevant to our watch regarding Vera Therapeutics' Phase 3 ORIGIN 3 trial. 2. **Alterity Therapeutics' ATH434 in MSA**: The search results show "FDA Confirms Single Phase 3 Trial Sufficient for ATH434 NDA in MSA". This directly relates to our watch: "Monitor the initiation of pivotal Phase 3 trial activities for ATH434 in Multiple System Atrophy (MSA) following FDA agreement." Let's fetch the details of these two developments to get precise information, quotes, and links. I will also do a specific search for both. First, let's search for "atacicept" "FDA" "approval" or "Vera Therapeutics" "accelerated approval" to find the official press release or news article from the last day or two.

Let's fetch the official press release or news details from Vera Therapeutics or FDA to get precise quotes on Trutakna (atacicept-vymj) approval and the status of the Phase 3 ORIGIN 3 confirmatory trial. This relates to our watch `019f3ec3-9518-7baa-a4e4-19e437e0557f` (Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN). Let's fetch `https://ir.veratx.com/news-releases/news-release-details/vera-therapeutics-receives-fda-accelerated-approval-trutaknatm`.

I will record an event for the watch `019f3ec3-9518-7baa-a4e4-19e437e0557f` (or wait, let's see: the watch is `Vera Therapeutics Phase 3 ORIGIN 3 eGFR confirmatory results in IgAN` which is expected in Q3 2026. This is a one_shot watch. The accelerated approval happened, but the watch is specifically for the confirmatory eGFR results supporting traditional approval in Q3 2026. Let's see if we should write a finding for this accelerated approval. Yes, this is a major drug approval that fits the brief perfectly, and it's a monumental milestone for Vera Therapeutics (their first drug approval, TRUTAKNA / atacicept-vymj). Let's also research Alterity Therapeutics' ATH434 in MSA. Let's search for "Alterity Therapeutics" "ATH434" "Phase 3" "MSA" to find the recent clinical trial vanguard article or press release.

Let's fetch the Globenewswire release for Alterity Therapeutics: `https://www.globenewswire.com/news-release/2026/07/07/3323052/0/en/alterity-therapeutics-receives-fda-end-of-phase-2-meeting-minutes-confirming-registrational-pathway-for-ath434-in-multiple-system-atrophy.html` to get precise details. This will help us resolve/update the watch `019eae92-83f5-74ae-a749-89b5c8b3b09d` (Alterity Therapeutics ATH434 Phase 3 MSA trial initiation / agreement). Let's see: the watch description is "Monitor the initiation of pivotal Phase 3 trial activities for ATH434 in Multiple System Atrophy (MSA) following FDA agreement." Since the FDA has now officially confirmed the registrational pathway (via End-of-Phase 2 meeting minutes) and agreed that a single Phase 3 trial is sufficient, this is a massive milestone! Let's read the details.

This is fantastic! Let's check if there are other updates on some of our other watches. Let's run a search for "Replimune" or "Capricor" or other watches. First, let's search for "Replimune" "RP1" "advisory committee" or "FDA" to see if there is any update on the late July 2026 advisory committee meeting or resubmitted BLA for RP1 in advanced melanoma. Let's do a search.

These are great details. The BLA resubmission was accepted by the FDA on June 26, 2026, with an action date of August 2, 2026, and an advisory committee meeting expected in late July 2026. This is consistent with our existing watch and prior findings, but let's see if there are newer details or if the date for the advisory committee meeting has been set. Let's search for "Capricor" "deramiocel" "advisory committee" or "FDA" to see if there is any update on the July 29, 2026 meeting. Let's do a search.

Excellent. The Capricor Cellular, Tissue, and Gene Therapies Advisory Committee meeting is set for July 29, 2026. This confirms our watch `019f061f-f34a-7079-a276-d216329928b2` is on track. Let's check if there are other new developments. What about other watches? Let's see: - Achive Life Sciences cytisinicline NDA resubmission? - Amgen Tavneos FDA hearing submission (extended deadline July 29, 2026)? - Sobi BLA resubmission for NASP in uncontrolled gout? - MoonLake Phase 3 IZAR-1 trial of sonelokimab in PsA? - MoonLake HS BLA submission? - Australia H5N1 transmission? - ISS Russian Zvezda module air leaks? Let's run a search for "Amgen" "Tavneos" "hearing" or "ADVOCATE" to see if there is any news from the last month. Amgen's Tavneos watch has an extended deadline of July 29, 2026. Let's see if there's any early update.

I will fetch the Medscape article to get precise details about the Tavneos deadline extension and NEJM retraction. This will allow us to write a finding or update a thread / watch. Let's fetch `https://www.medscape.com/viewarticle/amgen-fights-keep-avacopan-market-amid-growing-concerns-2026a1000mm9`.

I will read the existing notes to see if we have a stable slug for Vera Therapeutics' atacicept or IgA nephropathy, so we can reuse or mint a new one.

I will write two notes: 1. Revise `vera-therapeutics-trutakna-fda-accelerated-approval-igan` to reflect that the FDA has officially granted accelerated approval on July 7, 2026. 2. Revise `amgen-tavneos-eu-revocation-us-fda-extension` to incorporate the latest details of the NEJM retraction (on June 29, 2026) and the official FDA deadline extension to July 29, 2026. Wait, let's look at `amgen-tavneos-eu-revocation-us-fda-extension` and `amgen-tavneos-fda-hearing-nejm-retraction`. They are already in the system. I will update `amgen-tavneos-eu-revocation-us-fda-extension` as the primary repository of this story. Let's write the note for Vera Therapeutics first. I will fetch `vera-therapeutics-trutakna-fda-accelerated-approval-igan` first to see its original content if needed, but since I have the exact fresh press release, I can update it directly with the stable slug `vera-therapeutics-trutakna-fda-accelerated-approval-igan`. Let's do that.

Now let's update the Amgen Tavneos note, incorporating the latest Medscape article and BMJ article about the July 29, 2026 deadline and the NEJM retraction. Wait, let's look at the prior slugs: `amgen-tavneos-eu-revocation-us-fda-extension` Let's see the title of that note: "Amgen's Tavneos Faces EU Revocation over Data Integrity as U.S. FDA Hearing Deadline is Extended and NEJM Retracts Pivotal Trial" Let's write a note using that slug `amgen-tavneos-eu-revocation-us-fda-extension` to update it with the latest verified details.

Let's check if there are other threads we can resolve or update. We have: - `019f1fe0-09fc-7028-9aca-1d1dd5636118` (Amgen Tavneos FDA hearing submission extended deadline) -> This is an ongoing watch or one_shot? It's one_shot, fire_date July 29, 2026. The deadline has been extended, but since July 29 has not yet occurred (current time is July 8, 2026), we should NOT resolve this watch yet, but we have updated the note. Let's keep it open. - Let's see if we should record any other watches or events. Wait, let's look at Alterity's ATH434. The watch `019eae92-83f5-74ae-a749-89b5c8b3b09d` (Alterity Therapeutics ATH434 Phase 3 MSA trial initiation) is a one_shot watch. The trigger is: "Fires when Alterity Therapeutics begins enrolling patients or initiates clinical sites for the Phase 3 ATH434 trial in MSA." Since they haven't initiated the Phase 3 trial yet (they plan to do so by year-end 2026, as confirmed by the EOP2 meeting minutes), this watch should remain open. Let's check if there are any other recent news items that we should search for or write a finding on. Let's do a search for other major clinical trials or approvals from the last week. For example, did we see anything about H5N1 in Australia recently? Let's check. Let's search for "Australia" "H5N1" "poultry" OR "wildlife" to see if there is any new transmission or case in the last week. Our watch `019f2f50-7f4d-7361-8f05-cdf170c2d727` is "Australia H5N1 transmission to poultry or local wildlife". Let's see if there are any updates.

I will read the latest ABC news article to get precise details about the H5N1 detections in Australia. It mentions South Australia confirming its second H5 bird flu case, and Western Australia investigating two more suspected detections. Let's fetch `https://www.abc.net.au/news/2026-07-08/second-case-of-h5-bird-flu-confirmed-in-sa/106893356`. This is highly relevant to our watch `019f2f50-7f4d-7361-8f05-cdf170c2d727` (Australia H5N1 transmission to poultry or local wildlife). Let's see if it has jumped to poultry or local resident wildlife yet, or if it is still restricted to migratory/wild seabirds. Let's fetch the page to find out.

This is a crucial, fresh detail! The H5N1 bird flu has not yet been detected in commercial poultry or non-migratory wild birds, nor has it become established in any part of Australia. The cases remain restricted to migratory seabirds (giant petrels). I will update the existing `australia-h5n1-avian-influenza-seabirds` note with these July 8, 2026 details. Let's write the note.

Now that I have updated the three relevant notes (Vera Therapeutics, Amgen Tavneos, and Australia's H5N1 bird flu), I will double-check if there are any other topics to cover. The Alterity Therapeutics EOP2 agreement is a highly notable regulatory development, but we do not have an existing note on it, and the watch is still forward-looking (for the *initiation* of the Phase 3 trial by year-end). Since the watch itself hasn't fired yet, and we are focusing on updating existing stories or adding critical new findings, let's see if we should create a new note for Alterity's ATH434 registrational pathway. Let's check if there's any other major finding. If not, I can finish the cycle. Let's finish the cycle now.

I have successfully completed the research cycle. ### Summary of Actions & Findings: 1. **Vera Therapeutics' Trutakna (atacicept-vymj) FDA Accelerated Approval:** * **What happened:** On July 7, 2026, the FDA officially granted accelerated approval to Trutakna as the first dual BAFF and APRIL inhibitor to reduce proteinuria in adults with primary IgA nephropathy (IgAN) at risk of disease progression. * **Key data:** Supported by the Phase 3 **ORIGIN 3** trial interim analysis showing a 46% reduction in proteinuria from baseline (a statistically significant 42% reduction compared to placebo). * **What's next:** The trial remains blinded to evaluate long-term kidney function decline via eGFR, with confirmatory results highly anticipated in **Q3 2026** (monitored under our active watch). * **Action taken:** Updated the existing note `vera-therapeutics-trutakna-fda-accelerated-approval-igan`. 2. **Amgen's Tavneos (avacopan) Crisis & Extended FDA Deadline:** * **What happened:** The FDA extended Amgen's deadline to respond to its voluntary withdrawal request to **July 29, 2026** (to allow Amgen to submit independent re-adjudication results from the Duke Clinical Research Institute). * **Scientific blow:** On June 29, 2026, *The New England Journal of Medicine* officially retracted the pivotal 2021 ADVOCATE trial paper supporting Tavneos's approval, citing post-unblinding data manipulation of nine patients. * **Action taken:** Updated the existing note `amgen-tavneos-eu-revocation-us-fda-extension`. 3. **Australia's H5N1 Avian Influenza Spread:** * **What happened:** On July 8, 2026, South Australia confirmed its second case of H5N1 in a giant petrel found on the Yorke Peninsula, and Western Australia flagged two more suspected cases. * **Reassurance:** Commercial poultry and local non-migratory wildlife remain unaffected. A massive 5,000 km coastal aerial survey conducted by South Australia showed no widespread mortalities, suggesting the virus remains isolated to migratory seabirds. * **Action taken:** Updated the existing note `australia-h5n1-avian-influenza-seabirds`.